Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Emerging Tumefactive Ms After Switching Therapy From Interferon-Beta to Fingolimod: A Case Report Publisher Pubmed



Harirchian MH1 ; Taalimi A1 ; Siroos B1
Authors

Source: Multiple Sclerosis and Related Disorders Published:2015


Abstract

We describe a case of tumefactive multiple sclerosis, based on characteristic imaging features and excluding alternative diagnoses, presented with relapse 18 weeks after switching betaferon to fingolimod. Recent reported cases of this paradoxical demyelinating reaction in a setting of fingolimod-related immune system alterations seem to be something more than an accidental event. Immune cell shifting underlying a genetic susceptibility factor has been suggested to participate in this disastrous adverse effect. It could be a warning sign which physicians should take it into account for better recognition of patients at risk and select candidates for this management. © 2015 Elsevier B.V. All rights reserved.
Related Docs
View other Related Docs
1. Tumefactive Rebound of Multiple Sclerosis After the Short-Term Cessation of Fingolimod: A Case Report, Multiple Sclerosis and Related Disorders (2020)
2. Tumefactive Demyelinating Lesions in a Patient With Multiple Sclerosis Developed Two Days After the Injection of Rituximab, Acta neurologica Taiwanica (2020)
3. Tumefactive Demyelinating Lesions in a Patient With Multiple Sclerosis Developed Two Days After the Injection of Rituximab, Acta Neurologica Taiwanica (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (9)
Abdolreaza Naser Moghadasi (4)
Other Related Docs
4. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
5. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
6. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)
7. Characterization of Cd4+ and Cd8+ T Cell Subsets and Interferon Regulatory Factor 4 (Irf4) in Ms Patients Treated With Fingolimod (Fty-720); a Follow-Up Study, Iranian Journal of Allergy# Asthma and Immunology (2018)
8. Covid-19 and Disease-Modifying Therapies in Patients With Demyelinating Diseases of the Central Nervous System: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)
9. An Interdependence Between Gapvd1 Gene Polymorphism, Expression Level and Response to Interferon Beta in Patients With Multiple Sclerosis, Journal of Neuroimmunology (2021)
10. Introduction to the Neuroimmunology of Multiple Sclerosis, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
11. Association of Cd58 Polymorphism With Multiple Sclerosis and Response to Interferon ß Therapy in a Subset of Iranian Population, Cell Journal (2015)
12. A Case of Dextrocardia Following Maternal Exposure to Generic Fingolimod During the First Trimester of Pregnancy, Multiple Sclerosis and Related Disorders (2018)
13. Tumefactive Multiple Sclerosis Variants: Report of Two Cases of Schilder and Balo Diseases, Iranian Journal of Child Neurology (2017)
14. Thrombotic Microangiopathy in Interferon-Beta-Treated Multiple Sclerosis Patient, Clinical Case Reports (2020)
15. Balo's Concentric Sclerosis: An Update and Comprehensive Literature Review, Reviews in the Neurosciences (2018)
16. Translational Neuroimmunology, Volume 8: Multiple Sclerosis, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
17. Evaluation of the Effect of Mannuronic Acid As a Novel Nsaid With Immunosuppressive Properties on Expression of Socs1, Socs3, Ship1, and Traf6 Genes and Serum Levels of Il-6 and Tnf-Α in Patients With Multiple Sclerosis, Journal of Clinical Pharmacology (2021)
18. Mechanisms and Potentials of Stem Cells in the Treatment of Multiple Sclerosis: The Unpaved Path, Multiple Sclerosis: A Mechanistic View (2016)
19. Sensory-Neural Hearing Loss As an Early Rebound Relapse After Fingolimod Cessation in Multiple Sclerosis, Iranian Journal of Otorhinolaryngology (2020)
20. Adverse Side Effects of Glatiramer Acetate and Interferon Beta-1A in Patients With Multiple Sclerosis: A Systematic Review of Case Reports, Current Journal of Neurology (2023)